The Market is Dominated by Three Key Manufacturers
The biobetters market is dominated by three key manufacturers. Pharmaceutical companies, such as Amgen Inc., Novo Nordisk A/S, and Sanofi S.A., are dominating the global biobetters market by generating over 75% of the revenue. The manufacturers in the biobetters market are mainly competing on the basis of their geographical reach, diverse product portfolio, pricing of different products, etc. They are mostly engaging in the partnerships, mergers, and acquisitions to enhance their revenue generation across the world. For example, in January 2018, Sanofi acquired Bioverativ Therapeutics Inc., the manufacturer of Eloctate. In April 2018, Servier acquired Shire’s oncology business segment to be able to offer products directly in the U.S.
Manufacturers are largely engaging in the promotional activities of the biobetters available in the market to enhance revenue generation.
Superior Efficacy and Lower Adverse Effects of Biobetters
Biobetters are manufactured to be the superior versions of the existing biologics in various aspects such as their therapeutic effect, dosing frequency, adverse effects, etc. In addition, they are designed to have superior efficacy as compared to marketed biologics. For example, the dosing frequency of Neulasta, a biobetter of Amgen’s blockbuster Neupogen, is once per chemotherapy cycle, as opposed to Neupogen, whose dosage frequency is once daily during the chemotherapy cycle. Moreover, the therapeutic efficacy of Neulasta is superior as compared to Neupogen, which is resulting in higher patient compliance for the same.
Similarly, Roche manufactured Mircera, a biobetter of Amgen’s Epogen. Epogen is used for the treatment of anemia in patients suffering from Chronic Kidney Disease (CKD) as well as chemotherapy-induced anemia. Due to a lower dosing frequency, patients tend to complete their full treatment cycle. Moreover, the availability of various self-administrable dosage forms saves frequent visits to healthcare settings, thus lowering the economic burden of disease management. Lesser dosing frequency, coupled with superior efficacy, means lesser economic burden of each scheduled dose administration.
Comparatively Easier and Cheaper Manufacturing Process
The manufacturing process of biobetters is similar to that of biologics, however, it involves the usage of various advanced methods such as pegylation (i.e., the addition of PEG), albumin replacement, etc. Various companies have used these methods successfully for the manufacturing of various biobetters. For example, Roche manufactured Mircera (a biobetter of Epogen), as well as a biobetter of its own drug Avonex by using the pegylation method. The regulatory approval pathway of biobetters is the same as that of biologics, which allows manufacturers to avoid unnecessary complex litigations under the Biologics Price Competition and Innovation Act (BPCIA). The development cost of biobetters is around US$ 500 million, and they require around 10 years for development, whereas biologics require an investment of around US$ 1,200 million and around 15 years for development. Although the development cost for biosimilars is around half of that of biobetters, their therapeutic efficacy is much more superior.
Increasing Number of Studies for the Manufacturing of Biobetters
Various large and medium-sized pharmaceutical and biopharmaceutical companies are looking to develop biobetters as the process of manufacturing is comparatively easier. Partnerships with various global players is enabling the regional market players to enhance their product offering as well as technology transfer in return for their higher regional reach. For example, more than 70% of the revenue generation of granulocyte colony stimulating factor biobetters is concentrated in developed market such as North America and Europe and hence, various manufacturers are looking to improve their product offerings in other regions.
Biobetters Market: Competitive Landscape
This part of the report consists of the profiles of the key players in the biobetters market based on their market shares, product offerings, differential strategies, marketing approach, and company dashboard. Some of the important players featured in the biobetters market report include Amgen Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi SA, SERVIER, Porton Biopharma Limited, Eli Lily and Company, Novo Nordisk A/S, Biogen Inc., CSL Behring GmbH, and Teva Pharmaceutical Industries Ltd., among others.
Biobetters are therapeutically more efficient medicines as compared to their respective originator biologic drugs. Biobetters can either have better efficacy, or low adverse effects, and sometimes both. Due to their superior efficacy, biobetters are also known to have lesser dosage frequency, which helps improve patient compliance.
Biobetters Market: About the Report
The company conducted a research study on the biobetters market for the forecast period 2019 to 2029. The report offers a comprehensive evaluation of the business opportunities prevailing in the biobetters market, with insights on the current trends, prevalence of various chronic diseases such as cancer, diabetes, etc., and the reimbursement as well as regulatory scenario in the biobetters market.
Biobetters Market: Segmentation
The report offers a comprehensive taxonomy of the market based on the drug class, indication, route of administration, distribution channel, and region. By drug class, the biobetters market is segmented into erythropoietin biobetters, G-CSF biobetters, interferon biobetter, insulin biobetters, monoclonal antibodies biobetters, anti-hemophilic factor, and others. By indication, the biobetters market is segmented into diabetes, cancer, renal disease, neurodegenerative disease, genetic disorders (hemophilia), and others. By route of administration, the biobetters market is segmented as subcutaneous and intravenous. By distribution channel, the biobetters market is segmented into hospitals pharmacies, retail pharmacies, and online pharmacies. The biobetters market has been analyzed across the regions of North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East & Africa (MEA).
Additional Questions Answered
Some of the additional questions addressed in this report on the biobetters market:
The market has been estimated based on a supply-demand approach. The market was first calculated based on the epidemiology of different chronic diseases in different regions/countries. Some of the other qualitative factors analyzed include the awareness level and the availability of biobetters for different indications. This information is further validated with rigorous primary research (which includes interviews, surveys, in-person interactions, and the viewpoints of seasoned analysts) and secondary research (which includes verified paid sources, authentic trade journals, and resourceful databases). The research study on the biobetters market also includes the top trends and the macro- as well as micro-economic factors shaping the biobetters market. With this approach, the report on the biobetters market estimates the industry attractiveness of every major segment in the market over the forecast period.
A recent market study published by the company “Biobetters Market: Global Industry Analysis 2014–2018 & Forecast, 2019–2029” consists of a comprehensive assessment of the most important market dynamics. After conducting thorough research on the historic as well as current growth parameters of the biobetters market, the growth prospects of the market can be obtained with maximum precision. The report features the unique and salient factors that are likely to significantly impact the development of the biobetters market during the forecast period. It can help market players modify their manufacturing and marketing strategies to envisage maximum growth in the biobetters market in the upcoming years. The report provides detailed information about the current and future growth prospects of the biobetters market in the most comprehensive manner for the better understanding of readers.
Chapter 01 – Executive Summary
The report commences with the executive summary of the biobetters market, which includes the summary of key findings and key statistics of the market. It also includes the market value (US$ million) estimates of the leading segments of the biobetters market.
Chapter 02 – Market Overview
Readers can find the detailed taxonomy and the definition of the biobetters market in this chapter, which will help them understand the basic information about the biobetters market dynamics and cost structure. A list of key distributors and suppliers, as well as a list of key market participants is included in the report.
Chapter 03 – Key Market Trends
The report provides the key market trends that are expected to impact the market growth significantly during the forecast period. Detailed industry trends are provided in this section, along with a new treatment approach and product innovations.
Chapter 04 – Key Success Factors
This section includes the key inclusions of the report. It includes the regulatory scenario, disease epidemiology, pipeline assessment, and reimbursement scenario for each region.
Chapter 05 – Global Market Demand/Consumption (Value or Size in US$ Mn) Analysis
This chapter includes a detailed analysis of the historical biobetters market, along with opportunity analysis in the future. Readers can also find the absolute opportunity from 2019 to 2020, and the incremental opportunity for the forecast period.
Chapter 06 – Market Background
This chapter includes a detailed analysis of the macro-economic factors, forecast factors, and market dynamics such as the drivers and restraints of the market, and opportunity analysis.
Chapter 07 – Global Biobetters Market Analysis 2014–2028 & Forecast 2019–2029, By Drug Class
Based on the type, the biobetters market is segmented into erythropoietin biobetters, G-CSF biobetters, interferon biobetter, insulin biobetters, monoclonal antibodies biobetters, antihemophilic factors, and others. In this chapter, readers can find information about the key trends and developments in the biobetters market and market attractiveness analysis based on the drug class.
Chapter 08 – Global Biobetters Market Analysis 2014–2028 & Forecast, 2019–2029, By Indication
Based on the indication, the biobetters market is segmented into diabetes, cancer, renal disease, neurodegenerative disease, genetic disorders (hemophilia), and others. In this chapter, readers can find information about the key trends and developments in the biobetters market and market attractive analysis based on indication.
Chapter 09 – Global Biobetters Market Analysis 2014–2028 & Forecast, 2019–2029, By Route of Administration
Based on the route of administration, the biobetters market is segmented into subcutaneous and intravenous. In this chapter, readers can find information about the key trends and developments in the biobetters market and market attractive analysis.
Chapter 10 – Global Biobetters Market Analysis 2014–2028 & Forecast, 2019–2029, By Distribution Channel
Based on the distribution channel, the biobetters market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. In this chapter, readers can find information about the key trends and developments in the biobetters market and market attractive analysis based on the distribution channel.
Chapter 11 – Global Biobetters Market Analysis 2014–2028 & Forecast, 2019–2029, By Region
This chapter explains how the biobetters market will grow across various geographic regions, such as North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East & Africa (MEA).
Chapter 12 – North America Biobetters Market Analysis 2014–2018 & Forecast, 2019–2029
This chapter includes a detailed analysis of the growth of the North America biobetters market, along with a country-wise assessment that includes the U.S. and Canada. Readers can also find the regional trends, regulations, and market growth based on the end users and countries in North America.
Chapter 13 – Latin America Biobetters Market Analysis 2014–2018 & Forecast, 2019–2029
Readers can find detailed information about several factors, such as the pricing analysis and the regional trends, which are impacting the growth of the Latin America biobetters market. This chapter also includes the growth prospects of the biobetters market in the leading LATAM countries such as Brazil, Mexico, and the Rest of Latin America.
Chapter 14 – Europe Biobetters Market Analysis 2014–2018 & Forecast, 2019–2029
Important growth prospects of the biobetters market based on its end users in several countries, such as Germany, the UK, France, Spain, Italy, Russia, BENELUX, and Rest of Europe, are included in this chapter.
Chapter 15 – East Asia Biobetters Market Analysis 2014–2018 & Forecast, 2019–2029
In this chapter, China, Japan, and South Korea are among the prominent countries in the region, which are the prime subjects of assessment to obtain the growth prospects of the East Asia biobetters market. Readers can find detailed information about the growth parameters of the East Asia biobetters market during the period 2019–2029.
Chapter 16 – South Asia Biobetters Market Analysis 2014–2018 & Forecast, 2019–2029
Readers can find important factors that can significantly impact the growth of the biobetters market in India, Thailand, Indonesia, Malaysia, and the rest of South Asia during the forecast period based on the market segmentation.
Chapter 17 – Oceania Biobetters Market Analysis 2014–2018 & Forecast, 2019–2029
In this chapter, Australia and New Zealand are the leading countries in the Oceania region, which are the prime subjects of assessment to obtain the growth prospects of the Oceania biobetters market.
Chapter 18 – MEA Biobetters Market Analysis 2014–2018 & Forecast, 2019–2029
This chapter provides information about how the biobetters market will grow in the major countries in the MEA region, such as North Africa, GCC Countries, South Africa, and the rest of MEA, during the period 2019–2029.
Chapter 19 – Market Structure Analysis
This chapter enables readers to understand the market structure based on the revenue generation of key market players.
Chapter 20 – Competition Landscape, Company Share and Company Profiles
In this chapter, readers can find a comprehensive list of all the leading stakeholders in the biobetters market, along with detailed information about each company, which includes the company overview, revenue shares, strategic overview, and recent company developments. Some of the market players featured in the report are Amgen Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi SA, SERVIER, Porton Biopharma Limited, Eli Lily and Company, Novo Nordisk A/S, Biogen Inc., CSL Behring GmbH, and Teva Pharmaceutical Industries Ltd., among others.
Chapter 21 – Assumptions and Acronyms
This chapter includes a list of acronyms and assumptions that provide a base to the information and statistics included in the report.
Chapter 22 – Research Methodology
This chapter helps readers understand the research methodology followed to obtain the various conclusions as well as important qualitative and quantitative information about the biobetters market.